Literature DB >> 35731183

Anncaliia algerae Microsporidiosis Diagnosed by Metagenomic Next-Generation Sequencing, China.

Chen Liu, Qin Chen, Ping Fu, Yun-Ying Shi.   

Abstract

We report a case of Anncaliia algerae microsporidia infection in an immunosuppressed kidney transplant recipient in China. Light microscopy and transmission electron microscopy initially failed to identify A. algerae, which eventually was detected by metagenomic next-generation sequencing. Our case highlights the supporting role of metagenomic sequencing in early identification of uncommon pathogens.

Entities:  

Keywords:  Anncaliia algerae; China; fungi; immunocompromised; kidney transplantation; metagenomics; microsporidiosis; myositis; next-generation sequencing; parasites; transplant recipients

Mesh:

Year:  2022        PMID: 35731183      PMCID: PMC9239868          DOI: 10.3201/eid2807.212315

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   16.126


Anncaliia algerae is an uncommon, yet emerging microsporidian parasitic pathogen that can affect immunocompromised patients and cause fatal myositis (,). We report a case of A. algerae microsporidiosis, which was initially missed by conventional light microscopy (LM) and subsequent transmission electron microscopy (TEM) of biopsied muscle but eventually identified by metagenomic next-generation sequencing (mNGS).

The Study

In March 2021, a 45-year-old male kidney transplant recipient in China was admitted to the hospital for a 2-month history of muscle pain. He was receiving prednisone, tacrolimus, and mycophenolate mofetil for maintenance immunosuppression. The patient did not have respiratory symptoms at admission. Physical examination showed low fever and tenderness and generalized weakness in all 4 limbs. Laboratory investigations revealed serum creatine kinase level within reference range but low CD4+ T lymphocyte count (45 cells/µL; reference range 471–1,220 cells/µL). Serum cytomegalovirus DNA was 1.64 × 102 copies/mL. Results of tests for heavy metals, parasites, and myositis-specific autoantibodies were negative. The patient was febrile (37.3°C) at admission. Although immunosuppressant drugs were tapered dramatically, and broad-spectrum antimicrobial drugs and ganciclovir were added, the patient remained febrile (Figure 1). Chest computed tomography (CT) imaging showed patchy irregular ground-glass opacity in the left upper lung lobe. Electromyography testing showed myogenic damage in the biceps brachii muscle. Magnetic resonance imaging of lower extremities revealed swollen soft tissue. Bronchoalveolar lavage (BAL) testing was negative for bacteria, fungi, and Pneumocystis jirovecii DNA.
Figure 1

Clinical course of a 45-year-old patient with Anncaliia algerae microsporidia infection, China. The upper section of the graph shows the body-temperature curve (black line); dotted black line indicates 37.2°, the upper limit of normal body temperature. Thick blue and green lines indicate medications administered; dashed thick blue line indicates a dosing frequency of every other day. Major events during the patient’s course are indicated by arrows on the x-axis. Asterisk on day 34 denotes the initial light microscopy, which failed to detect A. algerae spores. BALF, bronchoalveolar lavage fluid; CFP/SBT, cefoperazone/sulbactum; CT, computed tomography; FB, fiberoptic bronchoscopy; GCV, ganciclovir; GI, gastrointestinal; HD, hemodialysis; LM, light microscopy; MEM, meropenem; mNGS, metagenomic next-generation sequencing; MRI, magnetic resonance imaging; MXF, moxifloxacin; PIP/SBT, piperacillin/sulbactum; SMZ/TMP, sulfamethoxazole/trimethoprim; TEM, transmission electron microscopy.

Clinical course of a 45-year-old patient with Anncaliia algerae microsporidia infection, China. The upper section of the graph shows the body-temperature curve (black line); dotted black line indicates 37.2°, the upper limit of normal body temperature. Thick blue and green lines indicate medications administered; dashed thick blue line indicates a dosing frequency of every other day. Major events during the patient’s course are indicated by arrows on the x-axis. Asterisk on day 34 denotes the initial light microscopy, which failed to detect A. algerae spores. BALF, bronchoalveolar lavage fluid; CFP/SBT, cefoperazone/sulbactum; CT, computed tomography; FB, fiberoptic bronchoscopy; GCV, ganciclovir; GI, gastrointestinal; HD, hemodialysis; LM, light microscopy; MEM, meropenem; mNGS, metagenomic next-generation sequencing; MRI, magnetic resonance imaging; MXF, moxifloxacin; PIP/SBT, piperacillin/sulbactum; SMZ/TMP, sulfamethoxazole/trimethoprim; TEM, transmission electron microscopy. The patient’s myalgia and weakness worsened, his serum creatine kinase level increased (Appendix Figure 1), and watery diarrhea developed. Stool microscopy, gastroduodenoscopy, and colonoscopy revealed no specific abnormalities; repeated chest CT scans showed increased inflammatory exudation and bilateral pleural effusion. No specific findings were reported from the initial LM of the left biceps brachii biopsy specimen except for degradation and necrosis of myofibers. We performed a second fiberoptic bronchoscopy and sent BAL fluid for untargeted mNGS via NextSeq 550 (Illumina, https://www.illumina.com), which revealed P. jirovecii (142 sequence reads) and A. algerae (127 sequence reads) within 48 hours of receiving the specimen (Appendix Table 1, Figure 2, panel A). Because the previous biopsy results were negative and we were unfamiliar with A. algerae microsporidia, we performed a literature review and then reviewed the initial muscle biopsy again. We considered the possibility of a combined infection of P. jirovecii and A. algerae, and we consulted an infectious disease specialist who suggested adding oral sulfamethoxazole/trimethoprim (SMZ/TMP; 1,600/320 mg 3×/d), which might be effective against both pathogens. After SMZ/TMP treatment, the patient’s temperature returned to normal for 5 successive days before climbing to 37.8°C on day 43 of admission; we added oral albendazole (400 mg 2×/d) (Figure 1), according to published cases (,,). However, the patient’s condition continued to deteriorate. On day 51, he decided on comfort care and died 2 days later (Figure 1). On day 52, one day before the patient died, we discovered multiple oval organisms measuring 2–3 µm in scattered clusters under LM in the muscle biopsy sample (Figure 2, panels A–D). After the patient died, we performed mNGS using muscle tissue from the previous biopsy, which yielded 65,311 sequence reads mapped to A. algerae (Appendix Table 2, Figure 2, panel B). A. algerae was confirmed by subsequent PCR testing on muscle tissue, but PCR testing of the remaining BAL specimen yielded no findings because not enough fluid was available in the sample after previous examinations. Eventually, we identified A. algerae via TEM in the third sample section (Figure 1; Figure 2, panels E, F). We deposited the A. algerae sequences into the National Center for Biotechnology Information Sequence Read Archive (accession nos. SRR18339014 for the BAL sample, SRR18339013 for the muscle sample).
Figure 2

Light microscopy and transmission electron microscopy of left biceps branchii muscle biopsy tissue from a 45-year-old man with microsporidiosis caused by Anncaliia algerae, China. A–D) Light microscopy using different stains. A) Periodic acid-Schiff stain. Scale bar indicates 10 µm. Original magnification ×50. B) Gomori methenamine silver stain. Scale bar indicates 10 µm. Original magnification ×63. C) Warthin-Starry stain. Scale bar indicates 10 µm. Original magnification ×63. D) Toluidine blue stain. Scale bar indicates 10 µm. Arrows indicate myocytes replaced by aggregates of 2–3 µm ovoid organisms. Original magnification ×63. E, F) Transmission electron microscopy showing Anncaliia-like microsporidia. Scale bars indicate 500 nm. E) A mature spore with electron-dense exospore, electron-lucent endospore, and a single row of 6 to 8 polar tubule coils (arrows). Original magnification ×8,000. F) Proliferating form of microsporidia showing diplokaryotic nuclei (stars) with vesiculotubular structures extending from the meront cell membrane and aggregating in the host cell cytoplasm (arrows). Original magnification ×3,000.

Light microscopy and transmission electron microscopy of left biceps branchii muscle biopsy tissue from a 45-year-old man with microsporidiosis caused by Anncaliia algerae, China. A–D) Light microscopy using different stains. A) Periodic acid-Schiff stain. Scale bar indicates 10 µm. Original magnification ×50. B) Gomori methenamine silver stain. Scale bar indicates 10 µm. Original magnification ×63. C) Warthin-Starry stain. Scale bar indicates 10 µm. Original magnification ×63. D) Toluidine blue stain. Scale bar indicates 10 µm. Arrows indicate myocytes replaced by aggregates of 2–3 µm ovoid organisms. Original magnification ×63. E, F) Transmission electron microscopy showing Anncaliia-like microsporidia. Scale bars indicate 500 nm. E) A mature spore with electron-dense exospore, electron-lucent endospore, and a single row of 6 to 8 polar tubule coils (arrows). Original magnification ×8,000. F) Proliferating form of microsporidia showing diplokaryotic nuclei (stars) with vesiculotubular structures extending from the meront cell membrane and aggregating in the host cell cytoplasm (arrows). Original magnification ×3,000.

Conclusions

A. algerae is a microsporidial species that has been reported to cause human infections since 1999 (). Of 12 reported cases of human A. algerae infection (–), 11 were among immunocompromised patients (Table). Thus, immunodeficiency, as in this patient, appears to be a critical risk factor for A. algerae infection. Although the modes of A. algerae transmission to humans remain uncertain, waterborne transmission, either through ingestion of or exposure to spore-contaminated water, has been postulated as the most likely route (,,). This patient lived near ditches in a rural area of the warm and humid Sichuan Basin and was readily exposed to waters possibly contaminated by A. algerae spores.
Table

Clinical characteristics of 12 previously reported cases of human Anncaliia algerae microsporidia infection*

Case reports
Age, y/sex
Immunocompromised/underlying conditions
Related symptoms
Positive biopsy sample sites
Treatment
Outcome
Watts et al. 2014 (1)67/MY/RAMyalgiasVastus lateralisAlbendazoleSurvived

66/M
Y/RA
Myalgias
Vastus lateralis
NG
Died
Coyle et al. 2004 (2)
57/F
Y/RA
Myalgias
Quadriceps femoris
Albendazole
Died
Boileau et al. 2016 (3)
49/M
Y/CLL
Myalgias
Vastus lateralis
Albendazole and fumagillin
Survived
Sutrave et al. 2018 (4)
66/M
Y/GVHD
Myalgias
Vastus lateralis
Albendazole
Survived
Visvesvara et al. 1999 (5)
67/M
N/N
Eye discomfort
Cornea
Albendazole and fumagillin
Survived
Ziad et al. 2021 (6)
55/M
Y/psoriatic arthritis
Myalgias
Vastus lateralis, intercostal muscle, and tongue
Albendazole
Died
Visvesvara et al. 2005 (7)
11/M
Y/ALL
Skin lesions
Skin
NA
NA
Cali et al. 2010 (8)
69/M
Y/CLL
Hoarseness
False vocal cord
Albendazole
Died
Field et al. 2012 (9)
49/F
Y/lung transplant
Myalgias
Deltoid and tongue
NG
Died
Chacko et al. 2013 (10)
56/M
Y/kidney transplant
Myalgias
Deltoid
Albendazole
Died
Anderson et al. 2019 (11)60/MY/kidney and pancreas transplantSkin lesionsLower extremity, finger, tongue, urine, andsputumAlbendazoleDied

*ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; GVHD, graft-versus-host disease; NA, data not available; NG, treatment for A. algerae was not given because the patient was undiagnosed before death; RA, rheumatoid arthritis.

*ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; GVHD, graft-versus-host disease; NA, data not available; NG, treatment for A. algerae was not given because the patient was undiagnosed before death; RA, rheumatoid arthritis. A. algerae infection in humans primarily manifests as myositis (–), and in reports we reviewed, 5 (62.5%) of 8 case-patients who had A. algerae myositis died (Table). Because of fatality risk, early diagnosis and prompt interventions are crucial. To date, biopsy and microscopy remain the standard approaches in microsporidia identification (), and the role of mNGS has yet to be confirmed. Although LM is the fastest diagnostic tool for microsporidiosis, it has several limitations. First, LM is unable to identify the genus and species of microsporidia. Second, the actual turnaround time (5–7 days in our hospital) for LM varies among institutions, which could cause diagnostic delays. Third, the accuracy of LM diagnosis relies on laboratory conditions and microscopist experience. In addition, morphologic features of A. algerae spores overlap with those of other organisms, such as small yeasts, which has led to misdiagnosis under LM (,). Thus, familiarity with A. algerae spores and their appearance on histopathology preparations are crucial for rapid diagnosis. In this case, A. algerae spores initially were missed by the microscopist and were detected 2 weeks later during retrospective review because of the relatively long turnaround time. TEM remains the standard technique for determining the specific microsporidia genus by identifying the ultrastructural characteristics (). TEM examines a smaller area of tissue at one time but usually has a longer turnaround time than routine LM. TEM results are available in 1–2 days in some institutions, but turnaround time in our hospital takes ≈10–14 days. As an unbiased, culture-free method capable of detecting all potential pathogens, untargeted mNGS enables identification of unexpected or unknown organisms (). Compared with hypothesis-driven methods, such as PCR, shotgun mNGS is hypothesis-free, enables survey of all DNA and RNA in multiple samples en masse (), and generally takes 24–48 hours to produce results. However, mNGS is unlikely to replace conventional diagnostic testing because of its limitations, such as high cost (US $522 for DNA detection and $894 for both DNA and RNA in our hospital), lack of a unified workflow, and no standard methods for interpreting results (). Instead, mNGS can serve as a valuable adjunct tool in diagnosing uncommon or unexplained infections when conventional methods such as LM fail. Albendazole and fumagillin have been used to treat A. algerae infections in previously reported cases (Table). We have easy access to albendazole, but no access to fumagillin. SMZ/TMP was reported to have no effect against Enterocytozoon bieneusi microsporidiosis (), but data regarding effectiveness against A. algerae microsporidia were limited. Treatment was greatly delayed in this patient because of our lack of clinical experience with A. algerae microsporidia and the late microscopy findings. Early treatment, along with minimized immunosuppression, might be crucial for the successful management of A. algerae infection (,,). In conclusion, A. algerae microsporidia infection requires early diagnosis and prompt intervention. LM alone cannot identify microsporidia genus and species; thus, TEM or genomic sequencing are needed for correct diagnosis. As a sensitive, culture-independent approach, mNGS could be a promising adjunct tool for the early identification of uncommon pathogens, such as A. algerae and other microsporidia.

Appendix

Additional information on Anncaliia algerae microsporidiosis diagnosed by metagenomic next-generation sequencing, China.
  13 in total

1.  Isolation of Nosema algerae from the cornea of an immunocompetent patient.

Authors:  G S Visvesvara; M Belloso; H Moura; A J Da Silva; I N Moura; G J Leitch; D A Schwartz; P Chevez-Barrios; S Wallace; N J Pieniazek; J D Goosey
Journal:  J Eukaryot Microbiol       Date:  1999 Sep-Oct       Impact factor: 3.346

2.  Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen.

Authors:  Christina M Coyle; Louis M Weiss; Luther V Rhodes; Ann Cali; Peter M Takvorian; Daniel F Brown; Govinda S Visvesvara; Lihua Xiao; Jaan Naktin; Eric Young; Marcelo Gareca; Georgia Colasante; Murray Wittner
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

3.  A Fatal Case of Disseminated Microsporidiosis Due to Anncaliia algerae in a Renal and Pancreas Allograft Recipient.

Authors:  Neil W Anderson; Atis Muehlenbachs; Sana Arif; Jackrapong Bruminhent; Paul J Deziel; Raymund R Razonable; Mark P Wilhelm; Maureen G Metcalfe; Yvonne Qvarnstrom; Bobbi S Pritt
Journal:  Open Forum Infect Dis       Date:  2019-07-08       Impact factor: 3.835

4.  Public health importance of Brachiola algerae (Microsporidia)--an emerging pathogen of humans.

Authors:  Govinda S Visvesvara; Hercules Moura; Gordon J Leitch; David A Schwartz; Lihua X Xiao
Journal:  Folia Parasitol (Praha)       Date:  2005-05       Impact factor: 2.122

Review 5.  Microsporidiosis: human diseases and diagnosis.

Authors:  C Franzen; A Müller
Journal:  Microbes Infect       Date:  2001-04       Impact factor: 2.700

6.  Drug treatment of microsporidiosis.

Authors:  Sylvia F. Costa; Louis M. Weiss
Journal:  Drug Resist Updat       Date:  2000-12       Impact factor: 18.500

7.  Fatal disseminated Anncaliia algerae myositis mimicking polymyositis in an immunocompromised patient.

Authors:  Fouzia Ziad; Thomas Robertson; Matthew R Watts; Justin Copeland; Graham Chiu; David Wang; Damien Stark; Linda Graham; Clinton Turner; Richard Newbury
Journal:  Neuromuscul Disord       Date:  2021-06-18       Impact factor: 4.296

8.  Successful Treatment of Disseminated Anncaliia algerae Microsporidial Infection With Combination Fumagillin and Albendazole.

Authors:  Mélissa Boileau; José Ferreira; Imran Ahmad; Christian Lavallée; Yvonne Qvarnstrom; Simon F Dufresne
Journal:  Open Forum Infect Dis       Date:  2016-07-29       Impact factor: 3.835

Review 9.  Clinical metagenomics.

Authors:  Charles Y Chiu; Steven A Miller
Journal:  Nat Rev Genet       Date:  2019-06       Impact factor: 53.242

10.  Anncaliia algerae microsporidial myositis.

Authors:  Matthew R Watts; Renee C F Chan; Elaine Y L Cheong; Susan Brammah; Kate R Clezy; Chiwai Tong; Deborah Marriott; Cameron E Webb; Bobby Chacko; Vivienne Tobias; Alexander C Outhred; Andrew S Field; Michael V Prowse; James V Bertouch; Damien Stark; Stephen W Reddel
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.